Evidence map›Paper›PMID 22760463›Full record

GuidelineSchmerz (Berlin, Germany)2012

[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].

C Sommer, W Häuser, R Alten, F Petzke, M Späth, T Tölle, N Uçeyler, A Winkelmann, E Winter, K J Bär and 1 more

Abstract readConsensus StatementMeta-AnalysisPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Schmerz (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults.The Cochrane database of systematic reviews · 2017
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Cognitive behavioural therapies for fibromyalgia.The Cochrane database of systematic reviews · 2013
    Pooled it
  7. Article
  8. Article
  9. Assessing the Impact of Antidepressants on Cancer Treatment: A Retrospective Analysis of 14 Antineoplastic Agents.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Milnacipran for the Treatment of Fibromyalgia.Health psychology research · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

C SommerNeurologische Klinik, Universitätsklinikum Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Deutschland. sommer@uni-wuerzburg.de
W Häuser
R Alten
F Petzke
M Späth
T Tölle
N Uçeyler
A Winkelmann
E Winter
K J Bär
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011. MATERIALS AND

methodsThe development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The recommendations were based on level of evidence, efficacy (meta-analysis of the outcomes pain, sleep, fatigue and health-related quality of life), acceptability (total dropout rate), risks (adverse events) and applicability of treatment modalities in the German health care system. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies. RESULTS AND

conclusionAmitriptyline and-in case of comorbid depressive disorder or generalized anxiety disorder-duloxetine are recommended. Off-label use of duloxetine and pregabalin can be considered in case of no comorbid mental disorder. Strong opioids are not recommended. The English full-text version of this article is available at SpringerLink (under "Supplemental").

Indexed as

AmitriptylineAnalgesicsAnalgesics, OpioidAntidepressive AgentsAnxiety DisordersCombined Modality TherapyComorbidityCooperative BehaviorDuloxetine HydrochlorideFibromyalgiagamma-Aminobutyric AcidGermanyHumansInterdisciplinary CommunicationMajor Depressive DisorderOff-Label UseAmitriptylineAnalgesicsAnalgesics, OpioidAntidepressive AgentsDuloxetine Hydrochloridegamma-Aminobutyric AcidPregabalinThiophenes

Identifiers

PMID22760463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.